Magnesium Sulfate Therapy in Aluminum Phosphide (Celphos) Poisoning
Adult Dosing Recommendations
- Initial bolus for life‑threatening arrhythmias – The American Heart Association recommends administering 1–2 g magnesium sulfate intravenously (diluted in 10 mL dextrose) for patients with cardiac arrest, torsades de pointes, or polymorphic ventricular tachycardia with QT prolongation. 1
- Rapid infusion for acute cardiotoxicity – The same guidance advises delivering the bolus over 2–5 minutes to achieve prompt therapeutic levels in severe cardiotoxicity. [2][3]
Pediatric Dosing Recommendations
- Weight‑based initial bolus – For children with severe cardiotoxicity, the American Heart Association suggests an initial dose of 25–50 mg/kg (maximum 2 g) given intravenously or intra‑osseously over 10–20 minutes. 1
- Continuous infusion (“rule of 6”) – The American Academy of Allergy, Asthma & Immunology recommends a maintenance infusion calculated as 0.6 × body weight (kg) = mg of magnesium diluted to 100 mL saline; infusing at 1 mL/h provides approximately 0.1 µg/kg/min. 4
Safety Monitoring
- Neuro‑muscular toxicity surveillance – Deep tendon reflexes should be checked regularly; loss of reflexes signals impending magnesium toxicity. 2
- Immediate reversal agents – Calcium gluconate 10 % (15–30 mL) or calcium chloride 10 % (5–10 mL) should be kept at the bedside for rapid IV administration if toxicity develops, as calcium antagonizes magnesium’s cardiac effects. 2
Management of Refractory Cases
- Advanced circulatory support – When arrhythmias persist despite adequate magnesium replacement, the American Heart Association advises consideration of veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO) for refractory cardiogenic shock or cardiac arrest. 3
Contraindications / Pitfalls
- Avoid indiscriminate use – Routine magnesium administration is not recommended in undifferentiated cardiac arrest without evidence of aluminum phosphide poisoning or torsades de pointes, as it provides no benefit. 1
Strength of evidence: The cited recommendations are based on expert consensus and observational studies; specific levels of evidence were not detailed in the source material.
Management of Cardiac Arrhythmias in Aluminium Phosphide Poisoning
Primary Indication: Cardiac Arrhythmias
- The American Heart Association recommends intravenous magnesium sulfate for patients with QT prolongation due to medication or acquired factors who develop recurrent torsades de pointes, particularly in the context of aluminium phosphide poisoning 5, 6
- The American College of Cardiology guidelines support the use of magnesium sulphate for torsades de pointes and polymorphic VT with prolonged QT interval in aluminium phosphide poisoning 5, 6
Dosing Protocol and Electrolyte Management
- The American Heart Association guidelines recommend maintaining potassium ≥4.0 mmol/L and magnesium ≥2.0 mmol/L, with magnesium sulphate dosing as needed to achieve these targets 5, 6
Critical Safety Monitoring
- Patients with renal failure can develop magnesium toxicity at lower doses, with cardiac effects including AV block 7, bradycardia 6, and cardiac arrest 5
- Calcium gluconate or calcium chloride should be immediately available for reversal of magnesium toxicity, with monitoring for adverse effects including flushing, sweating, hypotension, and respiratory paralysis 5, 6
Advanced Therapies for Refractory Cases
- If recurrent torsades de pointes cannot be suppressed with IV magnesium, increasing heart rate with atrial or ventricular pacing or isoproterenol is recommended 5, 6
- For refractory cardiogenic shock or cardiac arrest despite maximal medical therapy including magnesium, VA-ECMO is a reasonable consideration 7
Management of Aluminum Phosphide Poisoning
Rationale for Magnesium Sulfate Use
- The American Heart Association guidelines support magnesium sulfate for torsades de pointes and polymorphic VT with prolonged QT interval (Class IIb, LOE C) in patients with aluminum phosphide poisoning, which can cause cardiac arrhythmias 8, 9